Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
주식 순위 #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
주가
$193.62
시가총액
$150.08B
변동 (1일)
2.76%
변동 (1년)
184.69%
국가
GB
거래 AstraZeneca PLC (AZN)

카테고리

AstraZeneca PLC (AZN)의 P/E 비율
April 2026 기준 P/E 비율 TTM: 29.13
AstraZeneca PLC의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 29.13입니다. 2023년 말 기준 P/E 비율은 34.81였습니다.
AstraZeneca PLC의 P/E 비율 기록 (2000 ~ 2026)
매년 말 P/E 비율
연도 P/E 비율 변화
2026 (TTM) 29.13 -1.17%
2024 29.47 -15.33%
2023 34.81 -45.59%
2022 63.97 -95.78%
2021 1.52K 3,816.23%
2020 38.71 -60.41%
2019 97.77 111.14%
2018 46.30 65.64%
2017 27.95 28.54%
2016 21.75 -30.80%
2015 31.43 -57.80%
2014 74.47 166.92%
2013 27.90 195.73%
2012 9.43 44.66%
2011 6.52 -19.72%
2010 8.12 -7.58%
2009 8.79 -12.28%
2008 10.02 -13.27%
2007 11.55 -12.58%
2006 13.22 -25.11%
2005 17.65 12.05%
2004 15.75 -41.47%
2003 26.91 23.26%
2002 21.83 14.53%
2001 19.06 -45.76%
2000 35.14 0.00%
유사 기업 또는 경쟁사의 P/E 비율
회사 P/E 비율 P/E 비율 차이 국가
40.02 37.41%
US
22.15 -23.96%
US
91.61 214.53%
US
20.72 -28.87%
CH
16.41 -43.65%
US
P/E 비율 읽는 방법

P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.

P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.

양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.